NEWS CELLEGY PHARMACEUTICALS schon Plus 40% - 500 Beiträge pro Seite
eröffnet am 24.03.06 20:03:15 von
neuester Beitrag 25.03.06 14:00:36 von
neuester Beitrag 25.03.06 14:00:36 von
Beiträge: 3
ID: 1.049.801
ID: 1.049.801
Aufrufe heute: 0
Gesamt: 1.712
Gesamt: 1.712
Aktive User: 0
ISIN: US15115L1035 · WKN: 903551
Feedback
CELLEGY PHARMACEUTICALS
Cellegy's Licensee for Rectogesic(TM) in Europe Has Reported the Successful Conclusion of EU MRP Process
3/24/2006
HUNTINGDON VALLEY, Pa., March 24, 2006 /PRNewswire-FirstCall via COMTEX/ --
Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY.OB) announced that ProStrakan Group plc, Cellegy's licensee for Rectogesic in Europe, reported today "the successful conclusion of the EU Mutual Recognition Procedure (MRP) for Rectogesic(TM)." ProStrakan indicated that the procedure was completed successfully shortly after the "day 90" target date of March 20, 2006. Rectogesic(TM) is a 0.4% topical nitroglycerin ointment indicated for the relief of pain associated with chronic anal fissures.
ProStrakan's announcement continued, "The first EU launch of the product was into the UK market in May 2005. Month-on-month in-market sales demonstrate significant growth. Following the successful conclusion of the MRP process, national licenses will be issued in due course in the 19 additional countries included in the MRP submission application. Launches in these other European territories will take place through the first half of 2007." The completion of the MRP process is an initial step in receiving marketing regulatory approval in each country. Under Cellegy's license agreement with ProStrakan, Cellegy is entitled to receive $250,000 for each marketing regulatory approval obtained in the first of any three countries out of France, Italy, Germany or Spain up to a maximum total amount payable of $750,000. Under Cellegy's previous agreements with PDI, Inc., PDI is entitled to receive one-half of these payments.
About Cellegy
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention; and, gastrointestinal disorders. Savvy(R) (C31G vaginal gel), a novel microbicide gel product for contraception and the reduction in transmission of HIV in women, is currently undergoing Phase 3 clinical studies in the United States and Africa.
Cellegesic(TM) (nitroglycerin ointment), branded Rectogesic outside the United States, is approved and is being marketed in the United Kingdom by ProStrakan, for the treatment of pain associated with chronic anal fissures. A similar formulation of Rectogesic is currently being sold in Australia, New Zealand, Singapore and South Korea.
Forward Looking Statements
This press release contains forward-looking statements. Investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties relate to, among other factors: completion, timing and outcome of clinical trials, including primarily the Savvy prevention and contraceptive Phase 3 studies; the timing and outcome of the FDA Advisory Committee that will review the Cellegesic NDA and the timing and outcome of FDA action following that review; and the need and ability to complete corporate partnerships and additional financings. PDI and Cellegy are currently in litigation regarding agreements between the two parties entered into in 2005, and PDI may contend that it is entitled to receive all milestone payments that may be received by Cellegy as described in this press release. For more information regarding risk factors, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and other filings with the Securities and Exchange Commission.
SOURCE Cellegy Pharmaceuticals, Inc.
Richard C. Williams, Chairman and Interim CEO, +1-650-616-2200, or Robert J. Caso, Vice President, Finance & CFO, +1-215-914-0900, ext. 603, both of Cellegy Pharmaceuticals, Inc. http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
© 2006 Stockgroup Media Inc. | Disclaimer
Cellegy's Licensee for Rectogesic(TM) in Europe Has Reported the Successful Conclusion of EU MRP Process
3/24/2006
HUNTINGDON VALLEY, Pa., March 24, 2006 /PRNewswire-FirstCall via COMTEX/ --
Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY.OB) announced that ProStrakan Group plc, Cellegy's licensee for Rectogesic in Europe, reported today "the successful conclusion of the EU Mutual Recognition Procedure (MRP) for Rectogesic(TM)." ProStrakan indicated that the procedure was completed successfully shortly after the "day 90" target date of March 20, 2006. Rectogesic(TM) is a 0.4% topical nitroglycerin ointment indicated for the relief of pain associated with chronic anal fissures.
ProStrakan's announcement continued, "The first EU launch of the product was into the UK market in May 2005. Month-on-month in-market sales demonstrate significant growth. Following the successful conclusion of the MRP process, national licenses will be issued in due course in the 19 additional countries included in the MRP submission application. Launches in these other European territories will take place through the first half of 2007." The completion of the MRP process is an initial step in receiving marketing regulatory approval in each country. Under Cellegy's license agreement with ProStrakan, Cellegy is entitled to receive $250,000 for each marketing regulatory approval obtained in the first of any three countries out of France, Italy, Germany or Spain up to a maximum total amount payable of $750,000. Under Cellegy's previous agreements with PDI, Inc., PDI is entitled to receive one-half of these payments.
About Cellegy
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention; and, gastrointestinal disorders. Savvy(R) (C31G vaginal gel), a novel microbicide gel product for contraception and the reduction in transmission of HIV in women, is currently undergoing Phase 3 clinical studies in the United States and Africa.
Cellegesic(TM) (nitroglycerin ointment), branded Rectogesic outside the United States, is approved and is being marketed in the United Kingdom by ProStrakan, for the treatment of pain associated with chronic anal fissures. A similar formulation of Rectogesic is currently being sold in Australia, New Zealand, Singapore and South Korea.
Forward Looking Statements
This press release contains forward-looking statements. Investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties relate to, among other factors: completion, timing and outcome of clinical trials, including primarily the Savvy prevention and contraceptive Phase 3 studies; the timing and outcome of the FDA Advisory Committee that will review the Cellegesic NDA and the timing and outcome of FDA action following that review; and the need and ability to complete corporate partnerships and additional financings. PDI and Cellegy are currently in litigation regarding agreements between the two parties entered into in 2005, and PDI may contend that it is entitled to receive all milestone payments that may be received by Cellegy as described in this press release. For more information regarding risk factors, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and other filings with the Securities and Exchange Commission.
SOURCE Cellegy Pharmaceuticals, Inc.
Richard C. Williams, Chairman and Interim CEO, +1-650-616-2200, or Robert J. Caso, Vice President, Finance & CFO, +1-215-914-0900, ext. 603, both of Cellegy Pharmaceuticals, Inc. http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
© 2006 Stockgroup Media Inc. | Disclaimer
INSIDER TRADING - Cellegy ein spannender Play
09:00 17.02.04
Die Experten vom Börsenbrief "INSIDER TRADING" halten den Titel von Cellegy Pharmaceuticals (ISIN US15115L1035/ WKN 903551) für einen hochspekulativen spannenden Play.
Die Biopharmaschmiede aus San Francisco sei im Jahr 2003 leider noch immer weit vom Break-Even entfernt gewesen. Das Unternehmen habe im 3. Quartal 2003 einen Verlust von 2,1 Mio. USD oder 0,10 USD je Aktie hinnehmen müssen, bei Umsätzen von 414.000 USD. 2003 sei aber dennoch für die Entwicklung des Unternehmens ein sehr erfolgreiches Jahr gewesen. Zudem deute alles darauf hin, dass 2004 noch besser werde.
So sei es für das Teterongel Fortigel sehr wahrscheinlich, dass man im 1. Halbjahr 2004 von der FDA grünes Licht erhalten werde. Fortigel sei ein Medikament zur Behandlung von männlichen Hypogonadismus, wobei der Markt für derartige Medikamente bis auf 250 bis 300 Mio. USD geschätzt werde. Die jüngste spektakuläre Kursrallye sei aber auf die Entwicklung des Darmmedikaments Cellegesic zurückzuführen. Am 27. Januar habe man hier die ersten Ergebnisse der klinischen Testphase III präsentiert, welche sehr überzeugend gewesen seien.
Die positiven Aussichten von Cellegy hätten auch Beneficial Owner John M. Gregory dazu veranlasst am 27. und 29. Januar für 5,6 Mio. USD seinen Anteil auf 29,1% am Grundkapital der Gesellschaft aufzustocken. Seine bisherigen Anlagen bei Cellegy hätten sich bereits bezahlt gemacht. Gregory habe ein Average Return von 30,6%.
Für die Experten vom "INSIDER TRADING" ist die Cellegy-Aktie ein hochspekulativer spannender Play. Das langfristige Kursziel sehe man bei 10 USD.
Quelle: aktiencheck.de
Diese Analyse ist nun schon über 2 Jahre her aber die 10 USD sind noch weit weg...
09:00 17.02.04
Die Experten vom Börsenbrief "INSIDER TRADING" halten den Titel von Cellegy Pharmaceuticals (ISIN US15115L1035/ WKN 903551) für einen hochspekulativen spannenden Play.
Die Biopharmaschmiede aus San Francisco sei im Jahr 2003 leider noch immer weit vom Break-Even entfernt gewesen. Das Unternehmen habe im 3. Quartal 2003 einen Verlust von 2,1 Mio. USD oder 0,10 USD je Aktie hinnehmen müssen, bei Umsätzen von 414.000 USD. 2003 sei aber dennoch für die Entwicklung des Unternehmens ein sehr erfolgreiches Jahr gewesen. Zudem deute alles darauf hin, dass 2004 noch besser werde.
So sei es für das Teterongel Fortigel sehr wahrscheinlich, dass man im 1. Halbjahr 2004 von der FDA grünes Licht erhalten werde. Fortigel sei ein Medikament zur Behandlung von männlichen Hypogonadismus, wobei der Markt für derartige Medikamente bis auf 250 bis 300 Mio. USD geschätzt werde. Die jüngste spektakuläre Kursrallye sei aber auf die Entwicklung des Darmmedikaments Cellegesic zurückzuführen. Am 27. Januar habe man hier die ersten Ergebnisse der klinischen Testphase III präsentiert, welche sehr überzeugend gewesen seien.
Die positiven Aussichten von Cellegy hätten auch Beneficial Owner John M. Gregory dazu veranlasst am 27. und 29. Januar für 5,6 Mio. USD seinen Anteil auf 29,1% am Grundkapital der Gesellschaft aufzustocken. Seine bisherigen Anlagen bei Cellegy hätten sich bereits bezahlt gemacht. Gregory habe ein Average Return von 30,6%.
Für die Experten vom "INSIDER TRADING" ist die Cellegy-Aktie ein hochspekulativer spannender Play. Das langfristige Kursziel sehe man bei 10 USD.
Quelle: aktiencheck.de
Diese Analyse ist nun schon über 2 Jahre her aber die 10 USD sind noch weit weg...
Fundamentale Kennzahlen Sbroker
2005 2006* 2007*
Ergebnis / Aktie 0,00 EUR 0,71 EUR n.v. EUR
Kurs-Gewinn-Verhältnis n.v. 0,73 n.v.
Cash-Flow / Aktie 0,00 EUR 0,00 EUR n.v. EUR
Kurs-Cash-Flow-Verhältnis n.v. n.v. n.v.
Dividende / Aktie 0,00 EUR 0,00 EUR n.v. EUR
Dividendenrendite 0,00% 0,00% n.v.
Ob für 2006 die Schätzung Ergebnis/Aktie stimmt bin ich mal gespannt...
2005 2006* 2007*
Ergebnis / Aktie 0,00 EUR 0,71 EUR n.v. EUR
Kurs-Gewinn-Verhältnis n.v. 0,73 n.v.
Cash-Flow / Aktie 0,00 EUR 0,00 EUR n.v. EUR
Kurs-Cash-Flow-Verhältnis n.v. n.v. n.v.
Dividende / Aktie 0,00 EUR 0,00 EUR n.v. EUR
Dividendenrendite 0,00% 0,00% n.v.
Ob für 2006 die Schätzung Ergebnis/Aktie stimmt bin ich mal gespannt...
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,12 | |
| -0,11 | |
| -0,98 | |
| -99,00 | |
| -0,08 | |
| - | |
| +2,63 | |
| -0,20 | |
| - | |
| - |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 223 | ||
| 99 | ||
| 91 | ||
| 80 | ||
| 53 | ||
| 47 | ||
| 45 | ||
| 42 | ||
| 41 | ||
| 32 |
